FedEx Set to Report Q4 Earnings After Market Close
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Earnings Expectations: FedEx is expected to report Q4 earnings of $5.95 per share, a 2% decline year-over-year, while revenue is projected at $24.03 billion, an 8.2% increase, indicating ongoing profitability improvements post-freight division spin-off.
- Stock Performance: FedEx shares have surged 40% year-to-date, significantly outperforming the broader market's 9% gain, reflecting strong market confidence in its growth potential, particularly driven by cost-cutting initiatives.
- Management Changes: This earnings report will mark the first call under interim CFO Claude Russ, with management likely to provide updates on long-term financial targets following the completion of the freight separation, clarifying the company's strategic direction.
- Cost-Cutting Initiatives: FedEx's Network 2.0 program will continue to focus on consolidating facilities and routes, with expectations of achieving over $1 billion in permanent cost savings through structural reductions and efficiency improvements, enhancing the company's competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FDX
Wall Street analysts forecast FDX stock price to fall
20 Analyst Rating
13 Buy
6 Hold
1 Sell
Moderate Buy
Current: 326.200
Low
210.00
Averages
315.05
High
365.00
Current: 326.200
Low
210.00
Averages
315.05
High
365.00
About FDX
FedEx Corporation provides customers and businesses worldwide with a portfolio of transportation, e-commerce, and business services. The Company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Its Federal Express segment includes express transportation, small-package ground delivery, and freight transportation. The Federal Express segment operates combined sales, marketing, administrative, and information-technology functions in shared service operations for United States customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Quarterly Earnings to Watch on June 23
- FedEx Earnings Expectations: FedEx is set to announce its quarterly earnings after the market closes, with analysts anticipating profit boosts from increased domestic package volumes in the U.S., marking the first earnings call since the interim CFO took over on June 1, generating significant market interest.
- Carnival's Q2 Results: Carnival will report its second-quarter results on Tuesday, providing investors with insights into booking trends and consumer demand, with analysts particularly focused on fuel cost pressures and the company's outlook for 2026, which could influence future performance.
- Cerebras' First Major Test: Cerebras is facing its first major earnings report as a public company, scheduled for after market close, with analysts highlighting revenue concentration as a critical issue, and investors will be keen to assess management's ability to broaden its customer base.
- Market Focus: The earnings reports on Tuesday will offer investors fresh insights into consumer sectors and AI infrastructure, with heightened anticipation surrounding the performance of these companies amid the current economic landscape.
See More
FedEx Set to Report Q4 Earnings After Market Close
- Earnings Expectations: FedEx is expected to report Q4 earnings of $5.95 per share, a 2% decline year-over-year, while revenue is projected at $24.03 billion, an 8.2% increase, indicating ongoing profitability improvements post-freight division spin-off.
- Stock Performance: FedEx shares have surged 40% year-to-date, significantly outperforming the broader market's 9% gain, reflecting strong market confidence in its growth potential, particularly driven by cost-cutting initiatives.
- Management Changes: This earnings report will mark the first call under interim CFO Claude Russ, with management likely to provide updates on long-term financial targets following the completion of the freight separation, clarifying the company's strategic direction.
- Cost-Cutting Initiatives: FedEx's Network 2.0 program will continue to focus on consolidating facilities and routes, with expectations of achieving over $1 billion in permanent cost savings through structural reductions and efficiency improvements, enhancing the company's competitive edge.
See More
Micron Stock May Slide 15% Post Earnings, Analyst Predicts
- Earnings Preview: Micron is set to release its earnings report this Wednesday, with analyst Jay Woods predicting a potential 15% decline in stock price, which could negatively impact investor sentiment, especially given that the stock has fallen six out of the last eight earnings reports with an average drop of 6.5%.
- Price Volatility: Micron's stock has surged over 300% this year, currently trading about 15% above its 20-day moving average; however, Woods warns that a pullback to $1,000 would represent a nearly 12% decline, prompting investors to closely monitor this development.
- Market Focus: Woods emphasizes that traders are highly attentive to Micron's performance, particularly as the stock has reached its sixth Fibonacci extension, a rare occurrence, and he believes the likelihood of it extending to $1,500 is low.
- Industry Insights: In addition to Micron, Woods mentions earnings reports from FedEx and Darden Restaurants, the latter serving as a barometer for the middle-aged consumer, while the upcoming Russell reconstitution on Friday is dubbed the biggest trading day of the year, likely affecting market liquidity.
See More
U.S. and Iran Make Significant Progress on Deal
- Workforce Growth: Nevada's workforce grew by 1.9% from April 2025 to April 2026, the highest increase among U.S. states, indicating a strong economic recovery and attracting more job seekers to the region.
- Greenspan's Passing: Former Federal Reserve Chairman Alan Greenspan passed away at 100 due to complications from Parkinson's disease, having led the Fed through significant events like the 1987 market crash and multiple economic crises, leaving a lasting impact on monetary policy.
- Starmer Resignation: U.K. Prime Minister Keir Starmer announced his resignation as Labour leader and prime minister following poor local election results and internal party turmoil, marking a pivotal moment as the country prepares for its seventh prime minister since Brexit.
- Record Box Office: Disney and Pixar's
See More
U.S. and Iran Make Progress Towards Final Deal Amid Tensions
- Deal Progress: The U.S. and Iran made 'encouraging progress' towards a final deal within 60 days during high-level talks in Switzerland, aiming to end Middle Eastern conflicts, indicating positive diplomatic efforts.
- IAEA Inspections: Vice President JD Vance announced that Iran agreed to allow International Atomic Energy Agency inspectors back into the country, a move that could alleviate international concerns over Iran's nuclear program and promote regional stability.
- Oil Price Fluctuations: Following the announcement of the deal progress, oil prices fell, reflecting market optimism about future supply chain stability while also indicating investors' sensitivity to Middle Eastern tensions.
- Greenspan's Passing: Former Federal Reserve Chairman Alan Greenspan passed away at 100 due to complications from Parkinson's disease, having navigated multiple economic crises during his tenure, and reflections on his legacy may influence future monetary policy decisions.
See More
AbbVie Launches $11 Billion Bid for Apogee Therapeutics
- Acquisition Bid: AbbVie is planning to acquire Apogee Therapeutics for approximately $10.9 billion, a price that is about 60% higher than Thursday's closing price, which could significantly enhance AbbVie's market share in the dermatology treatment sector.
- Market Reaction: Apogee's stock surged over 50% in pre-market trading, reflecting a positive market response to the deal, while AbbVie's stock remained relatively unchanged, indicating investor confidence in its long-term strategy.
- Drug Potential: Apogee's new drug, Zumilokibart, is expected to enter Phase 3 trials later this year, and if approved, it will compete against Regeneron's Dupixent, which generated $17.8 billion in revenue last year, showcasing the market potential of Apogee's drug.
- Industry Outlook: AbbVie's acquisition not only diversifies its product pipeline but also strengthens its competitive position in the rapidly evolving dermatology market by potentially integrating Apogee's innovative therapies, thereby solidifying its leadership in the industry.
See More
Key Quarterly Earnings to Watch on June 23
- FedEx Earnings Expectations: FedEx is set to announce its quarterly earnings after the market closes, with analysts anticipating profit boosts from increased domestic package volumes in the U.S., marking the first earnings call since the interim CFO took over on June 1, generating significant market interest.
- Carnival's Q2 Results: Carnival will report its second-quarter results on Tuesday, providing investors with insights into booking trends and consumer demand, with analysts particularly focused on fuel cost pressures and the company's outlook for 2026, which could influence future performance.
- Cerebras' First Major Test: Cerebras is facing its first major earnings report as a public company, scheduled for after market close, with analysts highlighting revenue concentration as a critical issue, and investors will be keen to assess management's ability to broaden its customer base.
- Market Focus: The earnings reports on Tuesday will offer investors fresh insights into consumer sectors and AI infrastructure, with heightened anticipation surrounding the performance of these companies amid the current economic landscape.
See More
FedEx Set to Report Q4 Earnings After Market Close
- Earnings Expectations: FedEx is expected to report Q4 earnings of $5.95 per share, a 2% decline year-over-year, while revenue is projected at $24.03 billion, an 8.2% increase, indicating ongoing profitability improvements post-freight division spin-off.
- Stock Performance: FedEx shares have surged 40% year-to-date, significantly outperforming the broader market's 9% gain, reflecting strong market confidence in its growth potential, particularly driven by cost-cutting initiatives.
- Management Changes: This earnings report will mark the first call under interim CFO Claude Russ, with management likely to provide updates on long-term financial targets following the completion of the freight separation, clarifying the company's strategic direction.
- Cost-Cutting Initiatives: FedEx's Network 2.0 program will continue to focus on consolidating facilities and routes, with expectations of achieving over $1 billion in permanent cost savings through structural reductions and efficiency improvements, enhancing the company's competitive edge.
See More
Micron Stock May Slide 15% Post Earnings, Analyst Predicts
- Earnings Preview: Micron is set to release its earnings report this Wednesday, with analyst Jay Woods predicting a potential 15% decline in stock price, which could negatively impact investor sentiment, especially given that the stock has fallen six out of the last eight earnings reports with an average drop of 6.5%.
- Price Volatility: Micron's stock has surged over 300% this year, currently trading about 15% above its 20-day moving average; however, Woods warns that a pullback to $1,000 would represent a nearly 12% decline, prompting investors to closely monitor this development.
- Market Focus: Woods emphasizes that traders are highly attentive to Micron's performance, particularly as the stock has reached its sixth Fibonacci extension, a rare occurrence, and he believes the likelihood of it extending to $1,500 is low.
- Industry Insights: In addition to Micron, Woods mentions earnings reports from FedEx and Darden Restaurants, the latter serving as a barometer for the middle-aged consumer, while the upcoming Russell reconstitution on Friday is dubbed the biggest trading day of the year, likely affecting market liquidity.
See More
U.S. and Iran Make Significant Progress on Deal
- Workforce Growth: Nevada's workforce grew by 1.9% from April 2025 to April 2026, the highest increase among U.S. states, indicating a strong economic recovery and attracting more job seekers to the region.
- Greenspan's Passing: Former Federal Reserve Chairman Alan Greenspan passed away at 100 due to complications from Parkinson's disease, having led the Fed through significant events like the 1987 market crash and multiple economic crises, leaving a lasting impact on monetary policy.
- Starmer Resignation: U.K. Prime Minister Keir Starmer announced his resignation as Labour leader and prime minister following poor local election results and internal party turmoil, marking a pivotal moment as the country prepares for its seventh prime minister since Brexit.
- Record Box Office: Disney and Pixar's
See More
U.S. and Iran Make Progress Towards Final Deal Amid Tensions
- Deal Progress: The U.S. and Iran made 'encouraging progress' towards a final deal within 60 days during high-level talks in Switzerland, aiming to end Middle Eastern conflicts, indicating positive diplomatic efforts.
- IAEA Inspections: Vice President JD Vance announced that Iran agreed to allow International Atomic Energy Agency inspectors back into the country, a move that could alleviate international concerns over Iran's nuclear program and promote regional stability.
- Oil Price Fluctuations: Following the announcement of the deal progress, oil prices fell, reflecting market optimism about future supply chain stability while also indicating investors' sensitivity to Middle Eastern tensions.
- Greenspan's Passing: Former Federal Reserve Chairman Alan Greenspan passed away at 100 due to complications from Parkinson's disease, having navigated multiple economic crises during his tenure, and reflections on his legacy may influence future monetary policy decisions.
See More
AbbVie Launches $11 Billion Bid for Apogee Therapeutics
- Acquisition Bid: AbbVie is planning to acquire Apogee Therapeutics for approximately $10.9 billion, a price that is about 60% higher than Thursday's closing price, which could significantly enhance AbbVie's market share in the dermatology treatment sector.
- Market Reaction: Apogee's stock surged over 50% in pre-market trading, reflecting a positive market response to the deal, while AbbVie's stock remained relatively unchanged, indicating investor confidence in its long-term strategy.
- Drug Potential: Apogee's new drug, Zumilokibart, is expected to enter Phase 3 trials later this year, and if approved, it will compete against Regeneron's Dupixent, which generated $17.8 billion in revenue last year, showcasing the market potential of Apogee's drug.
- Industry Outlook: AbbVie's acquisition not only diversifies its product pipeline but also strengthens its competitive position in the rapidly evolving dermatology market by potentially integrating Apogee's innovative therapies, thereby solidifying its leadership in the industry.
See More
